Drug Topics December 25, 2023
In addition to the numerous adalimumab (Humira) biosimilars that launched this year, multiple new biosimilar products were approved by the FDA in 2023.1 These products included an additional adalimumab biosimilar, an IL-6 receptor antagonist for rheumatoid arthritis and juvenile idiopathic arthritis, and a biosimilar to ustekinumab (Stelara) indicated for multiple inflammatory diseases.
References
1. Biosimilar product information. FDA. Reviewed November 1, 2023. Accessed November 28, 2023. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
2. Celltrion USA announces US FDA approval of Yuflyma (adalimumab-aaty), a high-concentration and citrate-free formulation of Humira (adalimumab) biosimilar. News release. Celltrion Healthcare. May 24, 2023. Accessed November 28, 2023. https://www.celltrionhealthcare.com/board/en_newslist/102
3. FDA approves first biosimilar to treat...
Today's Sponsors
Today's Sponsor